Redeploying to repurpose

With declining revenues from its information and contract study services, Gene Logic Inc. last week announced an expanded service model based on technology acquired from Millennium Pharmaceuticals Inc. GLGC says the acquisition completes its goal of being able to offer a complete line of drug discovery and development services throughout the value chain. For MLNM, the deal allows it to get paid for offloading unnecessary assets, including two shelved metabolic programs, as part of its strategy to focus resources on downstream development.

GLGC acquired a set of technology from MLNM, including in vivo compound imaging, in vitro pathway screening, predictive and genetic ADME capabilities and metabolomic technology, plus a team of six researchers...